VF
MRSN

Virtu Financial’s Mersana Therapeutics MRSN Stock Holding History

Virtu Financial’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-871
Closed -$28K – 1851
2023
Q3 		$28K Buy
+871
New +$41.4K ﹤0.01% 964
2022
Q4 		– Sell
-1,021
Closed -$173K – 1957
2022
Q3 		$173K Buy
+1,021
New +$166K 0.02% 925
2022
Q2 		– Sell
-531
Closed -$53K – 1882
2022
Q1 		$53K Buy
+531
New +$62K ﹤0.01% 1116
2021
Q4 		– Sell
-751
Closed -$177K – 2007
2021
Q3 		$177K Buy
+751
New +$219K 0.02% 953
2021
Q1 		– Sell
-916
Closed -$609K – 1871
2020
Q4 		$609K Buy
+916
New +$509K 0.07% 380

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Virtu Financial's MRSN Position: Q4 2023 in Review

Virtu Financial sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 871 shares — an estimated $28K sold.

Virtu Financial first reported a position in MRSN in Q4 2020 and held it in 5 quarters. The position peaked at $609K in Q4 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Virtu Financial reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Virtu Financial sold 871 Mersana Therapeutics shares in Q4 2023, an estimated $28K.
  • Virtu Financial first reported a position in Mersana Therapeutics in Q4 2020 and held it in 5 quarters.
  • Virtu Financial's Mersana Therapeutics position peaked at $609K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Virtu Financial's 13F filing for Q4 2023, filed 26 Feb 2024.